1 Neuroblastoma Treatment Drugs Market Overview
1.1 Product Overview and Scope of Neuroblastoma Treatment Drugs
1.2 Neuroblastoma Treatment Drugs Segment by Type
1.2.1 Global Neuroblastoma Treatment Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Cyclophosphamide
1.2.3 Dinutuximab
1.2.4 Naxitamab
1.2.5 Doxorubicin Hydrochloride
1.2.6 Vincristine Sulfate
1.2.7 Other
1.3 Neuroblastoma Treatment Drugs Segment by Application
1.3.1 Global Neuroblastoma Treatment Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Neuroblastoma Treatment Drugs Market Size Estimates and Forecasts
1.4.1 Global Neuroblastoma Treatment Drugs Revenue 2017-2028
1.4.2 Global Neuroblastoma Treatment Drugs Sales 2017-2028
1.4.3 Neuroblastoma Treatment Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Neuroblastoma Treatment Drugs Market Competition by Manufacturers
2.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Neuroblastoma Treatment Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Neuroblastoma Treatment Drugs Manufacturing Sites, Area Served, Product Type
2.5 Neuroblastoma Treatment Drugs Market Competitive Situation and Trends
2.5.1 Neuroblastoma Treatment Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Neuroblastoma Treatment Drugs Players Market Share by Revenue
2.5.3 Global Neuroblastoma Treatment Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuroblastoma Treatment Drugs Retrospective Market Scenario by Region
3.1 Global Neuroblastoma Treatment Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Neuroblastoma Treatment Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.3.1 North America Neuroblastoma Treatment Drugs Sales by Country
3.3.2 North America Neuroblastoma Treatment Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.4.1 Europe Neuroblastoma Treatment Drugs Sales by Country
3.4.2 Europe Neuroblastoma Treatment Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Neuroblastoma Treatment Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Neuroblastoma Treatment Drugs Sales by Region
3.5.2 Asia Pacific Neuroblastoma Treatment Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.6.1 Latin America Neuroblastoma Treatment Drugs Sales by Country
3.6.2 Latin America Neuroblastoma Treatment Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Neuroblastoma Treatment Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Neuroblastoma Treatment Drugs Sales by Country
3.7.2 Middle East and Africa Neuroblastoma Treatment Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Neuroblastoma Treatment Drugs Historic Market Analysis by Type
4.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
4.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Neuroblastoma Treatment Drugs Price by Type (2017-2022)
5 Global Neuroblastoma Treatment Drugs Historic Market Analysis by Application
5.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
5.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Neuroblastoma Treatment Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 United Therapeutics
6.1.1 United Therapeutics Corporation Information
6.1.2 United Therapeutics Description and Business Overview
6.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 United Therapeutics Neuroblastoma Treatment Drugs Product Portfolio
6.1.5 United Therapeutics Recent Developments/Updates
6.2 Y-mAbs Therapeutics
6.2.1 Y-mAbs Therapeutics Corporation Information
6.2.2 Y-mAbs Therapeutics Description and Business Overview
6.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Portfolio
6.2.5 Y-mAbs Therapeutics Recent Developments/Updates
6.3 EUSA Pharma
6.3.1 EUSA Pharma Corporation Information
6.3.2 EUSA Pharma Description and Business Overview
6.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 EUSA Pharma Neuroblastoma Treatment Drugs Product Portfolio
6.3.5 EUSA Pharma Recent Developments/Updates
6.4 ANI Pharmaceuticals
6.4.1 ANI Pharmaceuticals Corporation Information
6.4.2 ANI Pharmaceuticals Description and Business Overview
6.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.4.5 ANI Pharmaceuticals Recent Developments/Updates
6.5 Baxter Healthcare
6.5.1 Baxter Healthcare Corporation Information
6.5.2 Baxter Healthcare Description and Business Overview
6.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Baxter Healthcare Neuroblastoma Treatment Drugs Product Portfolio
6.5.5 Baxter Healthcare Recent Developments/Updates
6.6 Ingenus Pharmaceuticals
6.6.1 Ingenus Pharmaceuticals Corporation Information
6.6.2 Ingenus Pharmaceuticals Description and Business Overview
6.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.6.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Pfizer Neuroblastoma Treatment Drugs Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Hikma Pharmaceuticals
6.8.1 Hikma Pharmaceuticals Corporation Information
6.8.2 Hikma Pharmaceuticals Description and Business Overview
6.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.8.5 Hikma Pharmaceuticals Recent Developments/Updates
6.9 Teva Pharmaceuticals
6.9.1 Teva Pharmaceuticals Corporation Information
6.9.2 Teva Pharmaceuticals Description and Business Overview
6.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Portfolio
6.9.5 Teva Pharmaceuticals Recent Developments/Updates
7 Neuroblastoma Treatment Drugs Manufacturing Cost Analysis
7.1 Neuroblastoma Treatment Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
7.4 Neuroblastoma Treatment Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Neuroblastoma Treatment Drugs Distributors List
8.3 Neuroblastoma Treatment Drugs Customers
9 Neuroblastoma Treatment Drugs Market Dynamics
9.1 Neuroblastoma Treatment Drugs Industry Trends
9.2 Neuroblastoma Treatment Drugs Market Drivers
9.3 Neuroblastoma Treatment Drugs Market Challenges
9.4 Neuroblastoma Treatment Drugs Market Restraints
10 Global Market Forecast
10.1 Neuroblastoma Treatment Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Neuroblastoma Treatment Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Neuroblastoma Treatment Drugs by Type (2023-2028)
10.2 Neuroblastoma Treatment Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Neuroblastoma Treatment Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Neuroblastoma Treatment Drugs by Application (2023-2028)
10.3 Neuroblastoma Treatment Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Neuroblastoma Treatment Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Neuroblastoma Treatment Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
